Xcout Intel
Neogap competitors & alternatives
The 12 closest competitors and alternatives to Neogap among biotechnology companies — ranked by similarity to what Neogap actually does, not by market-cap band.
Subscribe to see Neogap’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Neogap
Neogap Therapeutics is a privately held clinical-stage biopharmaceutical company founded in 2016 and located at the Cancer Center Karolinska in Stockholm, Sweden. The company focuses on immuno-oncology and is developing personalized therapies for cancer treatment.
Neogap at a glance
Neogap is a biotechnology company headquartered in Sweden. Its most recent funding round raised $9.2M in February 2026. Xcout tracks 9 named people at Neogap, including Samuel Svensson (CEO).
Neogap leadership
- Samuel SvenssonCEO
- Andrea SalménCOO
- Lars-Erik AnderssonActing CFO
- Guro GafvelinCTO
- Johan LundChairman of the board MD, PhD
- Hans GrönlundCSO and founder
3 more named people on record for Neogap, with roles, board committees and tenure — see the full roster →
Neogap funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $9.2M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Neogap competitors
Ranked by semantic similarity — how close each company is to Neogap by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Immatics is a biopharmaceutical company that develops T cell-based immunotherapies and bispecific product candidates to treat various types of cancer. The company focuses on precision targeting of the PRAME protein expressed in multiple solid tumors, serving cancer patients with high unmet medical needs.
Similar biotechnology company
Anocca is a fully integrated biopharmaceutical company founded in 2014 and headquartered in Södertälje, Sweden. The company focuses on building biotechnologies, processes, and infrastructure to decode T-cell immunity and develop new forms of engineered immunity.
Similar biotechnology company
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Similar biotechnology company
Tiankeya (also known as Beijing TCR Cure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in China, with operations in China and the United States. The company focuses on the innovation, development, and clinical translation of engineered T cell and immune cell therapies to treat cancer and solid tumors.
Similar biotechnology company
Celyad Oncology is a biopharmaceutical company headquartered in Mont-Saint-Guibert, Belgium, focused on the development of innovative therapies.
Similar biotechnology company
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Similar biotechnology company
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Similar biotechnology company
Epitopea is a transatlantic cancer immunotherapeutics company operating from Montreal, Canada, and Cambridge, United Kingdom. Backed by life-science investors, the company develops novel therapeutics utilizing its proprietary CryptoMap platform.
Similar biotechnology company
Go Therapeutics, Inc. is a biopharmaceutical company applying advances in glycoproteomics to develop novel antibody-based cancer therapies and immuno-oncology treatments. Headquartered in Natick, Massachusetts, the company has been active since 2014.
Similar biotechnology company
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Biotech
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Biotech
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Neogap and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Neogapand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →